Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The effects of short courses (5 days) of intravenous clodronate 300 mg daily were studied in 31 patients with active Paget's disease of bone. The diphosphonate induced a striking reduction in biochemical indices of disease activity, which was sustained for at least 6 months after withdrawal of treatment. Apparent resistance to further treatment in patients previously treated for Paget's disease was an artefact due to incomplete relapse before retreatment. There was no significant difference in the degree of suppression of alkaline phosphatase activity between patients given intravenous clodronate and 45 patients given clodronate 1.6 g daily by mouth for 6 months. Short-term intravenous clodronate provides a useful alternative strategy for the treatment of patients with Paget's disease.

Original publication

DOI

10.1016/s0140-6736(85)92253-6

Type

Journal article

Journal

Lancet

Publication Date

29/06/1985

Volume

1

Pages

1474 - 1477

Keywords

Administration, Oral, Alkaline Phosphatase, Biopsy, Bone and Bones, Clodronic Acid, Diphosphonates, Humans, Hydroxyproline, Infusions, Parenteral, Osteitis Deformans, Recurrence